What makes keytruda the leading drug for bladder cancer?

What keeps Keytruda in front of other bladder cancer treatments?

Keytruda works because it blocks the PD-1 receptor on T-cells, freeing them to attack tumor cells that hid behind the PD-L1 shield. This mechanism keeps producing durable responses in patients who have already received chemotherapy.

When does Keytruda receive new indications?

The FDA first approved it for advanced bladder cancer in 2017. It later gained approval for muscle-invasive disease in 2021 and for high-risk, non-muscle-invasive bladder cancer that does not respond to BCG in 2023. Each new label adds a fresh patient group and keeps the drug active in the oncology market.

How does Keytruda compete with other checkpoint inhibitors?

Keytruda shows higher objective response rates and longer overall survival than Opdivo in head-to-head data for urothelial carcinoma. Its broad label across early and late-stage disease gives it a larger total market than single-indication competitors such as Bavencio or Tecentriq.

What limits the entry of biosimilars or generics?

Keytruda is a biologic, not a genericizable drug. Its patents extend through at least 2028 on the base compound and to 2034 on formulation and dosing methods. Biosimilars cannot enter until those rights expire. [1]

When does the Keytruda patent expire?

The earliest possible entry of a biosimilar is 2028. Data exclusivity granted by the FDA runs to 2029, but the company holds composition-of-matter and method-of-use patents that stretch further. [1]

DrugPatentWatch.com